For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Attruby represents a genuine change. These novel therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the severity of the condition . People are now reporting improvements in the